Vyome's First Day of Trading as HIND Marks India's 79th Independence Day

Vyome Holdings (Nasdaq: HIND) rings Nasdaq Opening Bell, marking its first day of trading. The company, a clinical-stage healthcare holding targeting immuno-inflammatory and rare diseases, aims to create value for shareholders through a deep innovation pipeline and cost-effective operations. Vyome has no debt, and its board is heavily aligned with shareholders. The occasion also celebrates India's 79th Independence Day.

Vyome Holdings (Nasdaq: HIND) has marked its first day of trading on the Nasdaq Stock Market, ringing the opening bell today. The company, a clinical-stage healthcare holding focused on immuno-inflammatory and rare diseases, aims to deliver value to shareholders through a robust innovation pipeline and cost-effective operations.

Vyome's journey began today as it celebrated its first day of trading under the ticker "HIND." The company, based in Cambridge, MA, has a strong focus on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Vyome's unique positioning across the US-India innovation corridor allows it to deliver lasting value to shareholders while maintaining global standards of quality and safety.

The company's leadership, including Krishna Gupta, Chairman, and Shiladitya Sengupta, Founder and Associate Professor of Medicine at Harvard Medical School, expressed their commitment to shareholders. Gupta noted, "The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our stock being on Nasdaq." Sengupta highlighted the company's deep innovation pipeline and access to world-class talent in both the US and India.

Vyome's first day of trading also coincides with India's 79th Independence Day, marking a significant milestone for the company. The occasion underscores the special relationship between the US and India, which has been a driving force behind Vyome's growth and innovation.

The company's listing on the Nasdaq Stock Market follows a reverse merger with ReShape Lifesciences (Nasdaq: RSLS), which was approved by the Nasdaq Stock Market. The merger is expected to create a combined company with a strong focus on immuno-inflammatory diseases, a market exceeding $100 billion.

Vyome's board is heavily aligned with shareholders, with no debt, ensuring that every decision made will be in their best interests. The company's commitment to cost-effective operations and its deep innovation pipeline position it well to create value for shareholders in the future.

References:
[1] https://www.stocktitan.net/news/HIND/vyome-to-mark-first-day-of-trading-as-hind-with-nasdaq-opening-90eix6h0itv0.html
[2] https://www.marketscreener.com/news/vyome-announces-nasdaq-approval-of-merger-with-reshape-lifesciences-set-to-begin-trading-as-hind-ce7c51dbd08df52d